European urology oncology最新文献

{"title":"Targeted Prostate Health Checks, a Novel Screening System to Identify Men at Risk of Prostate Cancer: Real-world Evidence from More than 18 000 Prostate-specific Antigen Tests","authors":"Stephen Langley ,&nbsp;Santiago Uribe-Lewis ,&nbsp;Jennifer Uribe ,&nbsp;Hendrik Van Poppel ,&nbsp;Jeremy Goad ,&nbsp;Stephanie Bell ,&nbsp;Lee Foster ,&nbsp;Michele Pietrasik ,&nbsp;Alison Rooke ,&nbsp;Nicola Pereira ,&nbsp;Kishore Raja ,&nbsp;Catherine Hodges ,&nbsp;Marc Laniado ,&nbsp;Matthew Knight ,&nbsp;Edward Bosonnet ,&nbsp;Simon Bott","doi":"10.1016/j.euo.2025.10.007","DOIUrl":"10.1016/j.euo.2025.10.007","url":null,"abstract":"<div><h3>Background and objective</h3><div>The Targeted Prostate Health Check (TPHC) programme was set up to identify men with prostate cancer (PC) in the Surrey and Sussex region of England that was undetected during the COVID-19 era. We report outcomes for more than 18 000 prostate-specific antigen (PSA) checks using modern diagnostic techniques.</div></div><div><h3>Methods</h3><div>Men aged 50–70 yr, or 45–70 yr if Black or with a family history of PC, were identified via primary care (general practitioner [GP]) records. Text messages invited men to visit www.talkprostate.co.uk for information on PC and consent to PSA checks coordinated by Medefer, a virtual health care provider. Elevated age-related PSA (40–49 yr: &gt;2.5 ng/ml; 50–59 yr: &gt;3.5 ng/ml, 60–70 yr: &gt;4.5 ng/ml) or a level ≥3 ng/ml triggered referral for multiparametric magnetic resonance imaging (mpMRI) and, if indicated, local anaesthetic transperineal (LATP) biopsy. GPs were informed of the results.</div></div><div><h3>Key findings and limitations</h3><div>From 137 993 text messages inviting 66 911 individuals, 21 905 (33%) completed online surveys and consented to a PSA check. Of 18 317 men with a PSA result, 865 had elevated PSA (4.7%). After 817 mpMRI examinations, 344 patients underwent biopsy, 263 were diagnosed with PC, and 221 had International Society of Urological Pathology grade group 2–5 PC (84% of those diagnosed, 1.2% of those with a PSA test). The detection rate for grade group 2–5 PC was 26% with the age-related PSA cutoffs, and 25% with the ≥3 ng/ml cutoff. The average PC knowledge score increased by 1.87 points after the survey.</div></div><div><h3>Conclusions and clinical implications</h3><div>The TPHC programme screened men for PC untested during the COVID-19 pandemic without burdening primary care. Men were targeted from at-risk groups and their awareness was raised. Real-world data demonstrate the detection of significant PC via a modern pathway using MRI and LATP biopsies.</div></div>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"9 1","pages":"Pages 93-100"},"PeriodicalIF":9.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145444435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisiting Neoadjuvant Chemotherapy in Cisplatin-eligible Muscle-invasive Bladder Cancer","authors":"Javier Molina-Cerrillo ,&nbsp;James Catto ,&nbsp;Ashish M. Kamat ,&nbsp;Andrea Necchi ,&nbsp;Morgan Roupre^t ,&nbsp;Enrique Grande","doi":"10.1016/j.euo.2025.09.006","DOIUrl":"10.1016/j.euo.2025.09.006","url":null,"abstract":"<div><h3>Background and objective</h3><div>Management of muscle-invasive bladder cancer (MIBC) is evolving rapidly due to advances in systemic therapies and molecular understanding. Neoadjuvant cisplatin-based chemotherapy remains the cornerstone of cisplatin-eligible patients, supported by strong evidence of improved overall survival and pathological complete response. Phase 3 trials such as VESPER and NIAGARA have refined the standard of care by demonstrating the benefits of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin combination and chemoimmunotherapy, respectively. This review aims to summarize current and emerging neoadjuvant strategies and outline future directions toward a more individualized approach.</div></div><div><h3>Methods</h3><div>We reviewed the recent literature and pivotal clinical trial data evaluating neoadjuvant therapies for MIBC, with a focus on systemic chemotherapy, immunotherapy, combination regimens, novel agents, and biomarker-driven approaches. Emerging bladder-preserving strategies were also examined.</div></div><div><h3>Key findings and limitations</h3><div>Neoadjuvant cisplatin-based chemotherapy remains the established benchmark; however, the NIAGARA trial has provided the first phase 3 evidence supporting neoadj chemo and perioperative IO as a new therapeutic option. The addition of durvalumab to cisplatin-based chemotherapy resulted in a significant improvement in survival and response endpoints. Antibody-drug conjugates and biomarkers such as circulating tumor DNA and DNA damage response mutations are shaping a more personalized treatment paradigm. However, optimal regimen selection, sequencing of therapies, and robust methods for response assessment remain unresolved.</div></div><div><h3>Conclusions and clinical implications</h3><div>Recent therapeutic advances, particularly the integration of immunotherapy, novel agents, and biomarker-driven strategies, are redefining the neoadjuvant landscape in MIBC. Neoadjuvant treatment for MIBC is moving toward a biomarker-informed risk-adapted approach, integrating novel agents and multidisciplinary decision-making. Refinement of patient selection and treatment sequencing will be critical to improving outcomes and advancing personalized, precision-based care.</div></div>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"9 1","pages":"Pages 168-180"},"PeriodicalIF":9.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145257784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hall of Fame","authors":"","doi":"10.1016/S2588-9311(26)00033-7","DOIUrl":"10.1016/S2588-9311(26)00033-7","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"9 1","pages":"Page viii"},"PeriodicalIF":9.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146096142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Green Perspectives in Radiation Oncology","authors":"Jennifer Le Guevelou ,&nbsp;David Ali ,&nbsp;Stéphane Supiot","doi":"10.1016/j.euo.2025.05.020","DOIUrl":"10.1016/j.euo.2025.05.020","url":null,"abstract":"<div><div>The health care sector contributes 4.4% of global greenhouse gas emissions. Many countries are aiming for a carbon net-zero health care system by 2040–2050. Climate-smart practices in radiation oncology units include a progressive shift towards stereotactic body radiotherapy, the use of telemedicine, and strategies to streamline treatment workflows. Integration of geographic appropriateness in health care policies can also significantly mitigate the carbon footprint of clinical practice. Our rapid review assesses the environmental impact of climate-smart practices in radiation oncology departments, with a focus on management of prostate cancer.</div></div><div><h3>Patient summary</h3><div>Health care accounts for a significant proportion of greenhouse gas emissions. A number of actions are already possible in radiotherapy departments to limit their environmental impact, such as reducing the number of radiotherapy sessions, simplifying treatment planning, and using telemedicine. These strategies should be combined with government measures to ensure that all cancer patients have access to local care centers.</div></div>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"9 1","pages":"Pages 164-167"},"PeriodicalIF":9.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Penile Cancer Survivorship: Research Gaps in Psychosocial Health and Sexual Quality of Life","authors":"Cameron J. Britton ,&nbsp;Omar Almidani ,&nbsp;Avi S. Baskin ,&nbsp;Chad Ritch ,&nbsp;Omer Raheem ,&nbsp;Curtis A. Pettaway ,&nbsp;Kelvin A. Moses","doi":"10.1016/j.euo.2025.11.008","DOIUrl":"10.1016/j.euo.2025.11.008","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"9 1","pages":"Pages 1-3"},"PeriodicalIF":9.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145676895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Value of Prior Non–muscle-invasive Bladder Cancer for the Effectiveness of Neoadjuvant Chemotherapy in Localized Muscle-invasive Bladder Cancer: A Real-world Analysis of the BLADRAC Cohort","authors":"Elisabeth Grobet-Jeandin ,&nbsp;Elliott Diamant ,&nbsp;Pierre-Etienne Gabriel ,&nbsp;Alexandre De Olivera ,&nbsp;Théo Harber ,&nbsp;Marc Colombel ,&nbsp;Paul Hanquiez ,&nbsp;Vera Chatain ,&nbsp;Dimitri Vordos ,&nbsp;Igor Duquesne ,&nbsp;Mihnea Bogdan Borz ,&nbsp;Gregory Verhoest ,&nbsp;Anne Mauger De Varennes ,&nbsp;Louis Surlemont ,&nbsp;Marion Ghenassia ,&nbsp;Alexandra Masson-Lecomte ,&nbsp;Arthur Peyrottes ,&nbsp;Cédric Lebacle ,&nbsp;Peter Beniac ,&nbsp;Priscilla Léon ,&nbsp;Thomas Seisen","doi":"10.1016/j.euo.2025.11.006","DOIUrl":"10.1016/j.euo.2025.11.006","url":null,"abstract":"<div><h3>Background and objective</h3><div>It remains currently unknown whether the effectiveness of neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) is the same in patients with or without prior non–muscle invasive bladder cancer (NMIBC). This study aims to perform a real-world analysis of the predictive value of prior NMIBC for the effectiveness of NAC in patients undergoing RC for MIBC.</div></div><div><h3>Methods</h3><div>We included 2378 patients from the BLADRAC cohort who received RC with (<em>n</em> = 870; 37%) or without (<em>n</em> = 1508; 63%) NAC for primary (<em>n</em> = 1825; 77%) or secondary (<em>n</em> = 553; 23%) MIBC at 15 French centers from 2001 to 2023. Multivariable logistic regression models were fitted to identify the predictors of NAC delivery as well as those of pathological complete (pCR = [y]pT0N0) and pathological objective (pOR ≤[y]pT1N0) responses, while we assessed the predictors of recurrence-free (RFS), cancer-specific (CSS), and overall (OS) survival using multivariable Cox regression models. The heterogeneity of treatment effect of NAC according to the occurrence of prior NMIBC was determined further by testing the interaction terms between the occurrence of prior NMIBC and the effect of NAC within the models evaluating pathological and survival outcomes.</div></div><div><h3>Key findings and limitations</h3><div>Patients with secondary MIBC were significantly less likely to receive NAC (odds ratio [OR] = 0.63; 95% confidence interval [CI] = [0.5–0.79]; <em>p</em> &lt; 0.001) than those with primary MIBC. The use of NAC was an independent predictor of better pCR (OR = 6.02; 95% CI = [4.63–7.83]; <em>p</em> &lt; 0.001), pOR (OR = 5.08; 95% CI = [4.09–6.3]; <em>p</em> &lt; 0.001), RFS (HR = 0.61; 95% CI = [0.53–0.71]; <em>p</em> &lt; 0.001), CSS (HR = 0.57; 95% CI = [0.47–0.69]; <em>p</em> &lt; 0.001), and OS (HR = 0.61; 95% CI = [0.51–0.72]; <em>p</em> &lt; 0.001), while the occurrence of prior NMIBC was not significantly associated with any of these endpoints (all <em>p</em> &gt; 0.05). There was no significant interaction between the occurrence of prior NMIBC and the impact of NAC on pCR, pOR, RFS, CSS, and OS (all <em>p</em>_interaction &gt; 0.05). The study is limited by its retrospective design.</div></div><div><h3>Conclusions and clinical implications</h3><div>Our real-world data suggest that the occurrence of prior NMIBC could limit the access to NAC, while not predicting its effectiveness in patients treated with RC for localized MIBC.</div></div>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"9 1","pages":"Pages 116-124"},"PeriodicalIF":9.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145793275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: M. Roupret, A. Bertaut, G. Pignot, et al. ALBAN (GETUG-AFU 37): A Phase 3, Randomized, Open-label, International Trial of Intravenous Atezolizumab and Intravesical Bacillus Calmette–Guérin (BCG) Versus BCG Alone in BCG-naive High-risk, Non-muscle-invasive bladder cancer (NMIBC). Ann Oncol. In press. https://doi.org/10.1016/j.annonc.2025.09.017","authors":"David D’Andrea ,&nbsp;Shahrokh F. Shariat","doi":"10.1016/j.euo.2025.12.003","DOIUrl":"10.1016/j.euo.2025.12.003","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"9 1","pages":"Pages 203-204"},"PeriodicalIF":9.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145767681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cambridge kidney One-Stop Mass Investigation Clinic (CkOSMIC): A Nonrandomised Feasibility Study","authors":"Chiara Re ,&nbsp;James P. Blackmur ,&nbsp;Teele Kuusk ,&nbsp;Thomas J. Mitchell ,&nbsp;James N. Armitage ,&nbsp;Antony C.P. Riddick ,&nbsp;Lorraine Starling ,&nbsp;Hannah Fox ,&nbsp;Vineetha Thankappan Nair ,&nbsp;Sue Norman ,&nbsp;Claire Gilby ,&nbsp;James O. Jones ,&nbsp;Brent O’Carrigan ,&nbsp;Tristan Barrett ,&nbsp;Robert Bakewell ,&nbsp;Teikchoon See ,&nbsp;Nicholas Hilliard ,&nbsp;Simon Hilliard ,&nbsp;Akash Prashar ,&nbsp;Nadeem Shaida ,&nbsp;Grant D. Stewart","doi":"10.1016/j.euo.2025.09.007","DOIUrl":"10.1016/j.euo.2025.09.007","url":null,"abstract":"<div><h3>Background and objective</h3><div>Our aim was to evaluate the feasibility and outcomes of a one-stop renal mass biopsy (RMB) clinic at which same-day biopsy results were facilitated by the use of confocal microscopy.</div></div><div><h3>Methods</h3><div>The Cambridge kidney One-Stop Mass Investigation Clinic (CkOSMIC) was established in January 2024. Patients underwent an ultrasound (US)-guided biopsy, and the sample was assessed via a confocal laser microscopy scan, which provided results within minutes. Traditional histopathology processing was also conducted. A historical cohort of patients who underwent RMB according to the standard pathology pathway was used as the comparator. We assessed the feasibility, safety, and diagnostic accuracy, as well as the acceptability among patients and clinicians.</div></div><div><h3>Key findings and limitations</h3><div>Overall, CkOSMIC US-guided biopsy was conducted in 50 patients over a period of 12 mo, of whom 48 received a provisional diagnosis immediately. The sensitivity and specificity for identification of malignancy were 94% (29/31; 95% confidence interval [CI] 79–98%) and 100% (17/17; 95% CI 82–100%), respectively. There was complete agreement between confocal and final pathology for 91.7% (<em>n</em> = 44) of the patients, and partial concordance (cancer identified but equivocal histological subtype) for 8.3% (<em>n</em> = 4). Time from first consultation to a treatment decision, and time from biopsy to a treatment decision were significantly shorter in the CkOSMIC pathway (25 d, interquartile range [IQR] 15–42) than in the standard pathway (55 d, IQR 41–77; <em>p</em> &lt; 0.001). Time from biopsy to a treatment decision was also significantly shorter in the CkOSMIC pathway (0 d) than in the standard pathway (24 d, IQR 17–34; <em>p</em> &lt; 0.001). All participants were “satisfied” or “very satisfied” with the pathway.</div></div><div><h3>Conclusions and clinical implications</h3><div>CkOSMIC was feasible and showed high sensitivity and specificity in diagnosing cancer, while being safe and acceptable. It allows cancer targets to be met, reduces hospital visits and potentially reduces anxiety of delays in forming a treatment plan.</div></div>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"9 1","pages":"Pages 63-71"},"PeriodicalIF":9.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145299395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Constance Huck, Paul Sargos, and Alberto Bossi’s Letter to the Editor re: Markus Graefen, Fabian Falkenbach, Tobias Maurer, et al. Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.09.4144","authors":"Fabian Falkenbach ,&nbsp;Markus Graefen ,&nbsp;Burkhard Beyer","doi":"10.1016/j.euo.2025.11.012","DOIUrl":"10.1016/j.euo.2025.11.012","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"9 1","pages":"Pages 201-202"},"PeriodicalIF":9.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145676936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gender-based Differences in Psychosocial Well-being Among Bladder Cancer Survivors","authors":"Aidan S. Weitzner ,&nbsp;Aurora J. Grutman ,&nbsp;Alyssa Arbuiso ,&nbsp;Joseph Cheaib ,&nbsp;Carlos Rivera Lopez ,&nbsp;Nirmish Singla","doi":"10.1016/j.euo.2025.09.005","DOIUrl":"10.1016/j.euo.2025.09.005","url":null,"abstract":"<div><h3>Background and objective</h3><div>While gender disparities in bladder cancer are well documented in sexual and functional health domains, mental and social well-being among survivors are not elucidated fully. We aimed to investigate gender differences in mental well-being, social connectedness, and perceptions of respect among bladder cancer survivors.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional analysis from the <em>All of Us</em> Research Program of the National Institutes of Health, a nationwide cohort integrating survey responses and electronic health records (EHRs). Individuals with a diagnosis of malignant neoplasm of the bladder were included. The primary outcomes were self-reported overall mental and social health and EHR-documented depressive disorder. Multivariable logistic regression was adjusted for age, race, education/marital status, time since diagnosis, and comorbidities.</div></div><div><h3>Key findings and limitations</h3><div>Among 1085 individuals diagnosed with bladder cancer (319 women and 766 men), women had significantly higher odds of EHR-documented depressive disorder than men (adjusted odds ratio [interquartile range]: 2.86 [1.59, 3.82]; <em>p</em> &lt; 0.001). A higher proportion of women reported lacking companionship (<em>p</em> = 0.007), feeling isolated (<em>p</em> = 0.025), experiencing stress (<em>p</em> &lt; 0.001), and inability to cope (<em>p</em> &lt; 0.001). Female scores for general mental and social health were decreased but were not significantly different after adjusting for covariates. No gender differences were observed in perceived respect/courtesy from health care providers.</div></div><div><h3>Conclusions and clinical implications</h3><div>Women with bladder cancer experience disproportionate psychosocial burden compared with men, particularly related to depression and social isolation. Certain disparities were not apparent after adjustment for socioeconomic factors and comorbidities, underscoring the need to support patients with predisposing factors to adverse mental outcomes. Routine psychosocial screening should be integrated into bladder cancer survivorship to identify and support vulnerable individuals.</div></div>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"9 1","pages":"Pages 55-62"},"PeriodicalIF":9.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145502813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}